Health Enhancement Products, Inc. named Scott Freeman, MD to the post of Chief Science Officer as the company continues to build out its senior management team. Dr. Freeman will help guide the company through product development initiatives and compliance requirements. Dr. Freeman's expertise encompasses all therapeutic areas in clinical drug development including oncology, infectious disease, women's health, gastrointestinal, autoimmune, metabolic, and neurological disorders. Dr. Freeman served as Vice President of Clinical Development at Onyx Pharmaceutical (2001-2006) and was head of both clinical development and operations, which executed the clinical trials for renal cell, melanoma, liver, lung, and colorectal cancer. The Phase 1, 2 and 3 trials in kidney and liver cancer were successfully performed and led to NDA approval of Nexavar. Further, Dr. Freeman was a key leader in the regulatory strategy that led to FDA approval of Nexavar for renal cell and liver cancer.